Perspective Therapeutics

Perspective Therapeutics Current Assets

The Current Assets of Perspective Therapeutics (CATX) as of Nov 1, 2026 is 147.35 M USD. In the previous year, Current Assets was 232.53 M USD — a change of -36.63% (lower).

Current Assets

147.35 MUSD

YoY

-36.63%

Last updated:

Current Assets of Perspective Therapeutics is 2025 147.35 M USD. Current Assets of Perspective Therapeutics was 2024 232.53 M USD. It decreases by -36.63% lower compared to the previous year.

The Perspective Therapeutics Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2018
5.52 M USD
Jan 1, 2019
8.24 M USD
Jan 1, 2020
5.51 M USD
Jan 1, 2021
66.92 M USD
Jan 1, 2022
57.31 M USD
Jan 1, 2023
51.85 M USD
Jan 1, 2024
232.53 M USD
Jan 1, 2025
147.35 M USD
The Perspective Therapeutics Current Assets history
YEARCurrent AssetsYoY
147.35 MUSD-36.63%
232.53 MUSD+348.44%
51.85 MUSD-9.53%
57.31 MUSD-14.35%
66.92 MUSD+1,113.84%
5.51 MUSD-33.10%
8.24 MUSD+49.40%
5.52 MUSD-48.90%
10.80 MUSD-20.26%
13.54 MUSD-13.33%
15.62 MUSD-18.39%
19.14 MUSD+344.88%
4.30 MUSD+5.35%
4.08 MUSD+5.43%
3.87 MUSD+0.85%
3.84 MUSD-41.01%
6.51 MUSD-36.38%
10.23 MUSD-52.06%
21.34 MUSD+489.57%
3.62 MUSD-89.09%
33.19 MUSD+66,274.00%
50,000.00USD—
0.00USD—
0.00USD—
0.00USD-100.00%
33.00USD+13.79%
29.00USD-99.98%
137,273.00USD+44.81%
94,793.00USD+15.00%
82,431.00USD-38.94%
134,996.00USD-74.39%
527,025.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Perspective Therapeutics Stock analysis

What does Perspective Therapeutics do? Perspective Therapeutics Inc is a biotechnology company based in Seattle, United States, specializing in radiopharmaceutical development. The firm employs 163 people and focuses on advanced cancer treatments using proprietary technology that leverages the alpha-emitting isotope 212Pb. This approach delivers targeted radiation to cancer cells via specialized peptides, aiming to maximize efficacy while minimizing toxicity. Additionally, the company develops imaging diagnostics to personalize patient care. Its pipeline includes programs for metastatic melanoma and neuroendocrine tumors, which have entered Phase I/IIa clinical trials at academic institutions. Perspective Therapeutics also produces a 212Pb generator to secure essential isotopes for its clinical activities. The company has been listed on the market since May 31, 2002. Perspective Therapeutics is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Perspective Therapeutics stock

Current Assets of Perspective Therapeutics is 147.35 M USD in 2025.

Current Assets of Perspective Therapeutics changed from 232.53 M USD to 147.35 M USD, representing a -36.63% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Current Assets Perspective Therapeutics since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's Perspective Therapeutics historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Balance Sheet — Perspective Therapeutics

Total AssetsCurrent AssetsCash & EquivalentsReceivablesInventoryProperty, Plant & EquipmentGoodwillIntangible AssetsEquityLiabilitiesDebtCurrent LiabilitiesLong-term DebtShort-term DebtRetained EarningsBook Value per ShareTangible Book Value per ShareWorking CapitalInvestmentsAccounts PayableNon-Current AssetsShort-Term InvestmentsLong-Term InvestmentsNet DebtTreasury StockMinority InterestDeferred Tax LiabilitiesNet Tangible AssetsGoodwill/AssetsIntangibles/Assets

All Key Metrics — Perspective Therapeutics